Navigation Links
NeurogesX to Present at JMP Securities Healthcare Focus Conference
Date:10/1/2009

mbination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but a
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... 23, 2013 Amgen (NASDAQ: AMGN ) ... Healthcare Conference on Thursday, May 30, 2013, at the Westin ... 9:20 a.m. Eastern Daylight Time. Arvind Sood ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
(Date:5/24/2013)... Bay, Australia (PRWEB) May 24, 2013 ... show off their favorite sunglasses all while learning ... longer with replacement lenses. Contestants only need ... wearing their sunglasses and "like" The Sunglass Fix ... winning Sunglass fix is the largest lens ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... In a coup that surely made other ... of the Estetica Institute of the Palm Beaches performed eye ... popular morning show, “The Mo & Sally Morning Show.” The ... satisfaction with the results, giving Dr. DeLange and the team ... Beach Gardens, very valuable free publicity. , Dr. DeLange, the ...
(Date:5/24/2013)... 2013 CBT News.com recently announced the addition ... web-based retail automotive industry news organization with 12 years experience ... to join a group that’s so forward-thinking in their approach,” ... online video content is on the rise.” , Atlanta born ... and segued into advertising at Cycle News and Boating World. ...
Breaking Medicine News(10 mins):Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Dr. Greg DeLange of the Estetica Institute Recently Performed Eye Surgery on Both Members of Popular Morning Radio Team 2
... HealthDay Reporter , WEDNESDAY, July 27 (HealthDay News) ... emotional or behavioral issues often face tough social and ... , Tracking the progress of more than 1,450 students ... U.S. researchers found that one-third coped with special health ...
... research out of UCLA has found that Latinos living in ... the country are far less likely to spend for ... they do spend than the white population. ... they stay in the country, spending disparities remain large over ...
... discoveries in the field of cognitive neuroscience hold great ... a significant gap between such scientific discoveries and the ... New York Academy of Sciences and the ... conference on September 22-24, 2011 in Aspen, Colorado, ...
... BROOK, Ill. (July, 27, 2011) Using computed tomography (CT), ... lungs of patients with chronic obstructive pulmonary disease (COPD) that ... worsen. Their findings are published online in the journal ... the air sacs of the lungs, and is a leading ...
... risk factor for COPD, but have not accounted for ... Women,s Hospital, the University of Colorado, and National Jewish ... from the COPD Gene Study, capturing parental smoking and ... findings noted a strong risk factor for COPD when ...
... Brigham and Women,s Hospital (BWH) uses a new imaging technique, ... that are activated when patients with low back pain have ... published in the August issue of the journal Anesthesiology ... providing tools to objectively describe someone,s chronic pain which is ...
Cached Medicine News:Health News: Special Needs Kids Bullied More, Fare Poorly at School 2Health News: Special Needs Kids Bullied More, Fare Poorly at School 3Health News:Big gap exists on health care spending between Latinos and whites, study finds 2Health News:Conference: Improving K-12 education with cutting-edge cognitive neuroscience research 2Health News:CT shows changes in lungs associated with COPD flare-ups 2Health News:New imaging technique captures brain activity in patients with chronic low back pain 2
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Medicine Products: